New

Genetic Technologies

The AI engine Fit Assessment

Beta

Genetic Technologies focuses on women's health through predictive testing and provides diagnostic tools that enhance women's health outcomes.

Blurb

Genetic Technologies develops genetic risk assessment technology for breast cancer and colorectal cancer.

HQ Location

Australia

Founded

1989

Employees

51 - 200

Total funding raised

$2.00M

Last Funding Event

Post-IPO Equity, $2.00M, April 19, 2024

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Genomic and Genetic Testing

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.